259809-49-9

Usage

Uses

Used in Medicinal Chemistry:
6-(TERT-BUTOXYCARBONYL)-5,6,7,8-TETRAHYDRO-1,6-NAPHTHYRIDINE-2-CARBOXYLIC ACID is used as a chemical intermediate for the synthesis of various pharmaceutical compounds due to its carboxylic acid functionality, which allows for the formation of esters, amides, and other derivatives.
Used in Drug Development:
In the pharmaceutical industry, 6-(TERT-BUTOXYCARBONYL)-5,6,7,8-TETRAHYDRO-1,6-NAPHTHYRIDINE-2-CARBOXYLIC ACID is used as a potential lead compound for the development of new drugs, given its unique structure and the possibility of its biological activity.
Used in Chemical Research:
6-(TERT-BUTOXYCARBONYL)-5,6,7,8-TETRAHYDRO-1,6-NAPHTHYRIDINE-2-CARBOXYLIC ACID serves as a subject of study in chemical research to understand its properties, reactivity, and potential applications in various chemical processes.

Upstream product

• 259809-46-6 6-(tert-butoxycarbonyl)-2-cyano-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 259809-45-5 tert-butyl 1-oxo-7,8-dihydro-5H-1-lambda-5-1,6-naphthyridine-6-carboxylate 
• 259809-44-4 7,8-dihydro-5H-[1,6]naphthyridine-6-carboxylic acid tert-butyl ester 
• 1057855-79-4 5,6,7,8-tetrahydro-[1,6]naphthyridine-2-carboxylic acid methyl ester 
• 75510-02-0 6-benzyl-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 80957-68-2 5,6,7,8-tetrahydro-1,6-naphthyridine 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 259809-47-7 6-(tert-butoxycarbonyl)-2-methoxycarbonyl-5,6,7,8-tetrahydro-1,6-naphthyridine 

Downstream Products

• 1149333-41-4 1,1-dimethylethyl 2-[({1-[(3,4-dichlorophenyl)methyl]-1H-pyrazol-4-yl}amino)carbonyl]-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 
• 1149333-54-9 1,1-dimethylethyl 2-[({5-[(3,4-dichlorophenyl)methyl]-4-methyl-1,3-thiazol-2-yl}amino)carbonyl]-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 
• 1149333-42-5 1,1-dimethylethyl 2-[({5-[(4-chlorophenyl)methyl]-4-methyl-1,3-thiazol-2-yl}amino)carbonyl]-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate 

Relevant academic research and scientific papers

SUBSTITUTE 1, 6-NAPHTHYRIDINES FOR USE AS SCD INHIBITORS

The present invention relates to substituted tetrahydronaphthyridine (THN) compounds of the formula (I) and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity.

Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element

Our exploratory study was based on the concept that a non-amidine factor Xa (fXa) inhibitor is suitable for an orally available anticoagulant. We synthesized and evaluated a series of N-(6-chloronaphthalen-2-yl) sulfonylpiperazine derivatives incorporating various fused-bicyclic rings containing an aliphatic amine expected to be S4 binding element. Among this series, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine type 61 displayed orally potent anti-fXa activity and evident prolongation of prothrombin time (PT) with the moderate bioavailability in rats. The X-ray crystal analysis afforded an obvious binding mode that 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine and 6-chloronaphthalene respectively bound to S4 and S1 subsites. In this X-ray study, we discovered a novel intramolecular S-O close contact. Ab initio energy calculations of model compounds deduced that conformers with the most close S-O proximity were most stable. The Mulliken population analysis proposed that this energy profile was caused by both of electrostatic S-O affinity and N-O repulsion. The results of these calculations and X-ray analysis suggested a possibility that the restricted conformation effected the affinity to S4 subsite of fXa.